medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (2)


Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt

Saad N, Rude MK, Darcy M, Hanin JB, Wentworth A, Korenblat KM

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 215-221
Archivo PDF: 162.30 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding.N Engl J Med 2010; 362: 2370-9.

  2. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-34.

  3. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-47.

  4. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Eng J Med 2000; 342: 1701-7.

  5. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Poz zi M, Nicolini A, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-35.

  6. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites.Gastroenterology 2003; 124: 634-41.

  7. Harrod-Kim P, Saad WE, Waldman D. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites. J Vasc Interv Radiol 2006; 17: 1605-10.

  8. Parvinian A, Shah KD, Couture PM, Minocha J, Knuttinen MG, Bui JT, Gaba RC. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. J Vasc Interv Radiol 2013; 24: 941-6.

  9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.

  10. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Current Gastroenterology Reports 2010; 12: 1-6.

  11. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol- Hepatol 2004; 2: 1048-58.

  12. Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 2007; 13: 1515-20.

  13. Team RC: R: A Language and environment for statistical computing. In: R Foundation for Statistical Computing. Vienna, Austria, 2013.

  14. Therneau T.A Package for Survival Analysis in S. R package version 2.37-7.In., 2014.

  15. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.

  16. Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. J Vasc Interv Radiol 2005; 16: 615-29.

  17. Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879-85.

  18. Pan JJ, Chen C, Caridi JG, Geller B, Firpi R, Machicao VI, Hawkins IF, Jr., et al. Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years’ experience from a single tertiary medical center. J Vasc Interv Radiol 2008; 19: 1576-81.

  19. Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFEcovered stent grafts versus bare stents. Hepatology 2003; 38: 1043-50.

  20. Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis. J Vasc Interv Radiol 2002; 13: 155-61.

  21. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 2010; 16: 1373-8.

  22. Yang Z, Han G, Wu Q, Ye X, Jin Z, Yin Z, Qi X, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1718-25.




2020     |     www.medigraphic.com